Brand against brand · semaglutide and tirzepatide
Ozempic vs Zepbound
From the two FDA labels, read Published by PepVault
Ozempic is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Zepbound is tirzepatide, a GIP and GLP-1 receptor agonist, from Eli Lilly.
FDA approved Ozempic for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Zepbound is approved for weight loss and keeping it off, and obstructive sleep apnea in adults with obesity.
Label against label
| Compared | Ozempic | Zepbound |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| Class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| Approved for | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Weight reduction; obstructive sleep apnea with obesity |
| Forms | Multi-dose pen; Single-dose prefilled syringe; Tablet | Single-dose pen or vial; Multi-dose vial or KwikPen |
| How often | once a week or once a day | once a week |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 2.5 mg a week |
| Top dose on the label | 2 mg a week (injection); 9 mg a day (tablets) | 15 mg a week |
| Most reported side effect | Nausea, 20.3% on 1 mg (placebo 6.1%) | Nausea, 28% on 15 mg (placebo 8%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2017 | 2023 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Ozempic injection, once a week
Ozempic tablets, once a day
Zepbound, once a week

A missed dose, on each label
- Ozempic: A missed weekly injection is taken as soon as possible within 5 days. Past 5 days, the label skips it and the next dose comes on the usual day.
- Zepbound: Zepbound’s missed-dose rule gives 4 days (96 hours): within that window the dose is taken as soon as possible; after it, the dose is skipped and the week carries on as usual.
The trial evidence
Questions
What is the difference between Ozempic and Zepbound?
Ozempic is semaglutide, a GLP-1 receptor agonist; Zepbound is tirzepatide, a GIP and GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.
What are Ozempic and Zepbound approved for?
Ozempic is approved for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Zepbound is approved for weight loss and keeping it off, and obstructive sleep apnea in adults with obesity.
How often are Ozempic and Zepbound taken?
Ozempic is taken once a week or once a day, as an injection or a tablet; Zepbound once a week, as an injection.
What are the dose ranges of Ozempic and Zepbound?
On their labels, Ozempic runs 0.25 mg to 2 mg once a week or 1.5 mg to 9 mg once a day, and Zepbound 2.5 mg to 15 mg once a week. A prescriber sets the actual dose.
What is the most common side effect of Ozempic and Zepbound?
On Ozempic’s label: nausea, 20.3% on 1 mg (placebo 6.1%). On Zepbound’s: nausea, 28% on 15 mg (placebo 8%).
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use, FDA label on DailyMed (version 20, published Jun 10, 2026; read Nov 18, 2026)
- RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use, FDA label on DailyMed (version 14, published Aug 19, 2026; read Nov 18, 2026)
- ZEPBOUND (tirzepatide) injection, for subcutaneous use, FDA label on DailyMed (version 40, published Sep 2, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 209637 (Ozempic, the injection; application first approved 2017)
- Drugs@FDA, NDA 213051 (Ozempic, the tablets, added to the application by supplement 30 on Jan 30, 2026; application first approved 2019)
- Drugs@FDA, NDA 217806 (Zepbound, the injection; application first approved 2023)
PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Zepbound is a trademark of its owner.